Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,914 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06598527RecruitingPhase 3
Radiation and immunotherapy before surgery for lung cancer
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Guangzhou, GuangdongAges 18–75 - NCT06598306RecruitingPhase 1
Tarlatamab injection for advanced small cell lung cancer
This trial tests a new drug called tarlatamab, given as an injection under the skin (like a shot), for people with advanced small cell lung cancer that has worsened after chemotherapy. The goal is to see if this treatment can help shrink or slow down the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06598787RecruitingPhase 2
Study of a new drug for recurrent glioblastoma
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07690540Recruiting
Understanding immunotherapy response in endometrial cancer
This study looks at why some people with endometrial cancer respond well to immunotherapy. It uses samples of your tumor to help doctors better understand how to choose the right treatment for each person.
Milan, ItalyAges 18 years+ - NCT06723457RecruitingPhase 2
Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Chicago, IllinoisAges 18 years+ - NCT06603870RecruitingPhase 4
Preventing blood clots in cancer patients with catheter-related clots
This study tests whether a lower dose of the blood thinner apixaban (Eliquis) can safely prevent another blood clot in people with cancer who have a catheter-related clot in their upper arm or neck. It aims to find a balance between preventing clots and reducing bleeding risk.
Ottawa, OntarioAges 18 years+ - NCT06604338Recruiting
Genes and gut bacteria in recurrent pregnancy loss
This study looks at genes and gut bacteria in women who have had repeated miscarriages without a known cause. It aims to find possible reasons for these losses and could help improve future care.
Porto Alegre, Rio Grande do SulAges Any age - NCT06604689Recruiting
AI-guided brain radiation for EGFR-mutant lung cancer with brain mets
This study uses AI to help doctors decide the best way to use brain radiation for people with EGFR-mutant lung cancer that has spread to the brain. It aims to improve treatment planning and outcomes for those already taking a third-generation targeted therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06609850Recruiting
Comparing TACE plus lenvatinib with or without ablation for recurrent liver cancer
This trial compares two treatments for people whose liver cancer has come back (recurrent intermediate-stage hepatocellular carcinoma). One group gets TACE plus lenvatinib (a targeted therapy), the other gets TACE plus lenvatinib plus ablation (a procedure that destroys tumors with heat or cold). The goal is to see which combination works better.
Beijing, None SelectedAges 18–75 - NCT06609876Recruiting
Donafenib after ablation for recurrent liver cancer
This trial tests whether taking the drug donafenib after a procedure called ablation (which destroys liver tumors) can help keep your liver cancer from returning. It is for people whose liver cancer has come back within the past year and who have small, treatable tumors.
Beijing, None SelectedAges 18–75 - NCT06611345Recruiting
Tumor-treating fields with immunotherapy and chemo for bile duct cancer
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
HefeiAges 18–75 - NCT06612632RecruitingPhase 1/Phase 2
Retrying Immunotherapy for Solid Tumors After First Trial
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
BeijingAges 18 years+ - NCT06618235RecruitingPhase 1/Phase 2
Testing the virus therapy THEO-260 for ovarian cancer
This trial tests a new virus-based medicine called THEO-260 for people with a certain type of ovarian cancer that no longer responds to standard platinum chemo. The goal is to see if this treatment can shrink tumors or slow the cancer down.
MadridAges 18 years+ - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06623396RecruitingPhase 1
CAR T-cell therapy for stomach and esophagus cancer
This trial tests a new treatment called CAR T-cell therapy that targets a protein called mesothelin found on some cancer cells. It is for people with advanced or recurrent cancer of the stomach or esophagus that has spread or come back after prior treatment.
Basking Ridge, New JerseyAges 18 years+ - NCT06642545RecruitingPhase 2
New targeted drug combo for HER2-low breast cancer
This trial tests a new combination of targeted drugs (Disitamab Vedotin and RC148) against a standard chemotherapy (Abraxane) with or without an immunotherapy drug (Toripalimab) for advanced breast cancer that is HER2-low and hormone receptor-negative. The goal is to see if the new combination works better at shrinking tumors and slowing cancer growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06642948Recruiting
AI system for exercise rehab in breast cancer survivors
This study tests a new AI-based skeleton recognition system to guide rehabilitation exercises for breast cancer survivors. It may help reduce pain and improve mobility for those taking aromatase inhibitors.
ShanghaiAges Any age - NCT06658782Recruiting
MRI vs ultrasound for liver cancer detection in high-risk people
This trial compares two types of scans to see which detects liver cancer better in people at high risk. You would receive either an MRI with contrast or an ultrasound every 6 months to monitor for liver cancer.
Oxford, OxonAges 18 years+ - NCT06666712RecruitingPhase 1
Chronic brain infusion of topotecan for recurrent glioma
This trial tests a treatment called topotecan that is delivered directly into the brain through a small tube (convection-enhanced delivery). It is for people whose IDH-mutant glioma has come back despite standard treatment. The goal is to see if this approach can help control the tumor.
New York, New YorkAges 18 years+ - NCT06678048RecruitingPhase 2
Arsenous acid for hard-to-treat triple-negative breast cancer
This trial tests a medicine called arsenous acid for people with triple-negative breast cancer that has not responded to at least two prior treatments. If you join, you will get arsenous acid plus one of four chemotherapy drugs to see if the combination can shrink tumors.
Guangzhou, GuangdongAges 18–75 - NCT06680739RecruitingPhase 2
Study of immunotherapy for colorectal and endometrial cancer
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
BarcelonaAges 18 years+ - NCT06689293Recruiting
Stool test for follow-up after colorectal cancer treatment
This trial is testing whether a simple stool test (FIT) can replace some follow-up colonoscopies or CT scans for people who have been treated for colorectal cancer. If you are due for a routine check-up after your cancer surgery, you may be able to take this test at home instead of having a more invasive procedure.
NottinghamAges 18 years+ - NCT06695234Recruiting
Mindfulness program for cancer patients' wellbeing
This study tests a new mindfulness program designed to help people with cancer improve quality of life, manage pain, and feel better emotionally and spiritually. You would attend weekly online sessions for 8 weeks.
Derby, DerbyshireAges 18 years+ - NCT06696326Recruiting
New PET scan for prostate cancer detection
This study tests a new type of PET/CT scan that uses a special tracer (68Ga-MY6349) to better see prostate cancer in the body. It may help doctors find cancer that has come back or spread, so you can get the right treatment sooner.
Xiamen, FujianAges 18–90
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,914 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.